A review on hepatitis D: From virology to new therapies

Đăng ngày 11/29/2019 1:30:58 PM | Thể loại: | Lần tải: 0 | Lần xem: 1 | Page: 13 | FileSize: 1.47 M | File type: PDF
A review on hepatitis D: From virology to new therapies. Hepatitis delta virus (HDV) is a defective virus that requires the hepatitis B virus (HBV) to complete its life cycle in human hepatocytes. HDV virions contain an envelope incorporating HBV surface antigen protein and a ribonucleoprotein containing the viral circular single-stranded RNA genome associated with both forms of hepatitis delta antigen, the only viral encoded protein. Replication is mediated by the host cell DNA-dependent RNA polymerases. HDV infects up to72 million people worldwide and is associated with an increased risk of severe and rapidly progressive liver disease. Pegylated interferon-alpha is still the only available treatment for chronic hepatitis D, with poor tolerance and dismal success rate. Although the development of antivirals inhibiting the viral replication is challenging, as HDV does not possess its own polymerase, several antiviral molecules targeting other steps of the viral life cycle are currently under clinical development: Myrcludex B, which blocks HDV entry into hepatocytes, lonafarnib, a prenylation inhibitor that prevents virion assembly, and finally REP 2139, which is thought to inhibit HBsAg release from hepatocytes and interact with hepatitis delta antigen. This review updates the epidemiology, virology and management of HDV infection
HƯỚNG DẪN DOWNLOAD TÀI LIỆU

Bước 1:Tại trang tài liệu slideshare.vn bạn muốn tải, click vào nút Download màu xanh lá cây ở phía trên.
Bước 2: Tại liên kết tải về, bạn chọn liên kết để tải File về máy tính. Tại đây sẽ có lựa chọn tải File được lưu trên slideshare.vn
Bước 3: Một thông báo xuất hiện ở phía cuối trình duyệt, hỏi bạn muốn lưu . - Nếu click vào Save, file sẽ được lưu về máy (Quá trình tải file nhanh hay chậm phụ thuộc vào đường truyền internet, dung lượng file bạn muốn tải)
Có nhiều phần mềm hỗ trợ việc download file về máy tính với tốc độ tải file nhanh như: Internet Download Manager (IDM), Free Download Manager, ... Tùy vào sở thích của từng người mà người dùng chọn lựa phần mềm hỗ trợ download cho máy tính của mình  
1 lần xem

A review on hepatitis D: From virology to new therapies. Hepatitis delta virus (HDV) is a defective virus that requires the hepatitis B virus (HBV) to complete its life cycle in human hepatocytes. HDV virions contain an envelope incorporating HBV surface antigen protein and a ribonucleoprotein containing the viral circular single-stranded RNA genome associated with both forms of hepatitis delta antigen, the only viral encoded protein. Replication is mediated by the host cell DNA-dependent RNA polymerases. HDV infects up to72 million people worldwide and is associated with an increased risk of severe and rapidly progressive liver disease. Pegylated interferon-alpha is still the only available treatment for chronic hepatitis D, with poor tolerance and dismal success rate. Although the development of antivirals inhibiting the viral replication is challenging, as HDV does not possess its own polymerase, several antiviral molecules targeting other steps of the viral life cycle are currently under clinical development: Myrcludex B, which blocks HDV entry into hepatocytes, lonafarnib, a prenylation inhibitor that prevents virion assembly, and finally REP 2139, which is thought to inhibit HBsAg release from hepatocytes and interact with hepatitis delta antigen. This review updates the epidemiology, virology and management of HDV infection.

Nội dung

Journal of Advanced Research 17 (2019) 3–15 Contents lists available at ScienceDirect Journal of Advanced Research journal homepage: www.elsevier.com/locate/jare Review A review on hepatitis D: From virology to new therapies Nathalie Menthaa, Sophie Clémentb,⇑, Francesco Negrob,c, Dulce Alfaiatea a Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland b Division of Clinical Pathology, Geneva University Hospitals, 1211 Geneva, Switzerland c Division of Gastroenterology and Hepatology, Geneva University Hospitals, 1205 Geneva, Switzerland h i g h l i g h t s g r a p h i c a l a b s t r a c t Hepatitis D virus is a defective virus, dependent on hepatitis B virus for its assembly. Hepatitis D virus infection affects 62– 72 million people worldwide. Chronic hepatitis D is the most severe chronic viral hepatitis. Current interferon-based antiviral treatments have dismal efficiency and are poorly tolerated. Host-targeting molecules inhibiting the viral life cycle are currently in clinical development. a r t i c l e i n f o a b s t r a c t Article history: Received 2 January 2019 Revised 21 March 2019 Accepted 22 March 2019 Available online 29 March 2019 Keywords: Hepatitis delta virus Virus life cycle Chronic hepatitis Epidemiology Treatment Hepatitis delta management Introduction Hepatitis delta virus (HDV) is a defective virus that requires the hepatitis B virus (HBV) to complete its life cycle in human hepatocytes. HDV virions contain an envelope incorporating HBV surface antigen protein and a ribonucleoprotein containing the viral circular single-stranded RNA genome associated with both forms of hepatitis delta antigen, the only viral encoded protein. Replication is mediated by the host cell DNA-dependent RNA polymerases. HDV infects up to72 million people worldwide and is associated with an increased risk of severe and rapidly progressive liver disease. Pegylated interferon-alpha is still the only available treatment for chronic hepatitis D, with poor tolerance and dismal success rate. Although the development of antivirals inhibiting the viral replication is challenging, as HDV does not possess its own polymerase, several antiviral molecules targeting other steps of the viral life cycle are currently under clinical development: Myrcludex B, which blocks HDV entry into hepatocytes, lonafarnib, a preny-lation inhibitor that prevents virion assembly, and finally REP 2139, which is thought to inhibit HBsAg release from hepatocytes and interact with hepatitis delta antigen. This review updates the epidemiology, virology and management of HDV infection. 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). depends on the expression of the hepatitis B virus (HBV) surface antigen (HBsAg) in the same cell to complete its life cycle. HDV Hepatitis D or delta is caused by the hepatitis delta virus (HDV), a human pathogen first identified in 1977 [1]. HDV is a defective RNA virus that does not encode its own envelope proteins and Peer review under responsibility of Cairo University. ⇑ Corresponding author. E-mail address: sophie.clement@unige.ch (S. Clément). can enter hepatocytes not expressing HBsAg and efficiently repli-cate its genome and express the hepatis delta antigen (HDAg); however, no secretion of infectious particles occurs. Hepatitis D is hence the result of either an acute coinfection by HBV and HDV or a HDV superinfection of patients chronically infected with HBV. https://doi.org/10.1016/j.jare.2019.03.009 2090-1232/ 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 4 N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 Chronic hepatitis D (CHD) is arguably the most aggressive type of viral hepatitis and is associated with an increased risk of cirrho-sis, liver decompensation and hepatocellular carcinoma (HCC) [2], but the management of HDV has evolved little during the past years. The main treatment remains pegylated interferon-alpha (IFN-alpha), with unsatisfactory results. Nucleos(t)ide analogues specific for HBV have no effect on HDV replication. However, sev-eral host-targeting molecules with a specific impact on HDV life cycle are currently under development. Epidemiology Worldwide, 248 to 292 million people are chronically infected with HBV [3,4]. Based on these estimations, 15 to 20 million of these patients were initially thought to be also affected by HDV [5]. These figures were challenged by a recent meta-analysis, proposing that a staggering 62–72 million people may live with HDV worldwide [6], a prevalence almost two-times greater than that of human immunodeficiency virus (HIV) infection (estimated to infect 36.9 million persons in 2017, according to the World Health Organization). These estimates imply a disease burden much higher than previously considered and one that is still debated [7]. Indeed, the exact global prevalence of HDV infection remains unknown because of heterogeneous and non-standardised screening practices and the inaccessibility to testing in many endemic areas. In Mongolia, HDV infects 60% of the HBsAg-positive individu-als, corresponding to the highest reported prevalence worldwide [8]. Other highly affected areas include the Amazon basin [9], West Africa [10,11], the Mediterranean basin [12] and Eastern Europe [13]. In Western Europe, although high prevalence rates were described in Italy early after HDV identification, a subsequent decrease was documented as consequence of improved socio-economic conditions and mass vaccination campaigns against HBV [14,15]. HDV prevalence now seems to be very low in some European countries, and in close association with intravenous drug use (IVDU) [16]. However, no decrease has been observed in other areas, likely because of migration from endemic regions [17,18]. In the United States, HDV infection has for long been considered rare and screening recommendations are limited to high-risk pop-ulations [19]. Unfortunately, several recent studies highlight the presence of suboptimal testing rates and suggest that the preva-lence may be much higher that previously considered [20–22]. As HBV, HDV can be transmitted by blood and blood-derived products and sexual contact. Vertical transmission is however rare. In highly endemic populations, transmission occurs mainly through intrafamilial and iatrogenic spread [23] in association with poor hygiene conditions [24]. In low endemicity regions in the northern hemisphere, iatrogenic and intrafamilial transmission, while accounting for infections occurred in the past, are no longer common and IVDU is now the main transmission route [6]. Sexual transmission, although less frequent than for HBV or HIV, seems to be important in regions where HBV infection is endemic, such as Taiwan [25,26]. Virology Classification HDV is the smallest known virus infecting mammals, for which humans are the only natural reservoir. Other susceptible mam-malian hosts have been identified as well as used for research pur-poses; these include chimpanzees, tree shrews (both with HBV as a helper virus) and woodchucks (in the presence of the woodchuck hepatitis virus, WHV). Although HBV orthologues have been found in a variety of non-human mammals and have been shown to have potential cross-species infectivity [27], no HDV orthologue had been described until the very recent identification of HDV-like agents in birds and snakes [28,29]. Due to its distinct characteristics, HDV has been postulated to originate from plant viroids or cellular circular RNAs and is cur-rently the sole member of the Deltavirus genus [30–32]. There are eight HDV genotypes, highly heterogeneous, with up to 40% of sequence divergence [33]. Genotype 1 is present world-wide and is the predominant virus in Europe and North America. Genotype 3 is identified in South America, while genotypes 2 and 4 are common in East Asia and genotypes 5–8 are mainly found in Africa (refer to [34] for a review of genotype distribution). Although good quality studies are limited, different genotypes seem to be associated with distinct liver disease severity. In com-parison with genotype 1, genotypes 2 and 4 seem to cause milder liver disease. Genotype 2 in particular, has been associated to a lower incidence of cirrhosis, HCC and decreased mortality than genotype 1 in a prospective study conducted in Asia [35]. Genotype 3, on the other hand, is associated with a more severe course of acute infections and a higher risk of acute liver failure [36]. A co-evolution of HBV and HDV genotypes can be suggested by the frequency of specific genotype pairs, the most commonly reported being the combination of HDV genotype 3 with HBV genotype F [37]. However, these associations have been argued to merely result from geographic distribution, given these are not strict combinations [36] and HDV virion assembly has been shown to be possible with several HBV genotypes [38]. Viral structure HDV circulating virions were firstly characterised in chim-panzees infected with serum from an Italian chronic carrier [39]. As represented in Fig. 1. These 35–37 nm particles are composed of an envelope and a ribonucleoprotein (RNP). Since HDV is a defective virus and does not code for its own sur-face proteins, it uses the three forms of HBV surface proteins (small or S-HBsAg, medium or M-HBsAg and large or L-HBsAg) on which it depends to form its own envelope and egress and re-entry into hepatocytes. These proteins share a common C-terminus (S domain, the only constituent of S-HBsAg). M-HBsAg contains an N-terminal hydrophilic domain named PreS2 and, relative to M-HBsAg, L-HBsAg N-terminus consists of an additional domain named PreS1 [40]. The RNP, present both in viral particles and infected cells, con-tains the viral genome associated with both isoforms of the hepati-tis delta antigen (HDAg) — small, S-HDAg, and large, L-HDAg — forming a structure that is essential for the nuclear trafficking of HDV RNA and for viral assembly [41]. Although debate surrounds its complete characterisation, its assembly depends on the oligomerisation of HDAg molecules and the secondary structure of the HDV genome [42–45]. The HDV genome, whose complete structure was first reported in 1986, is a circular, covalently closed, single-stranded RNA of 1680 nucleotides with 74% internal base pairing, allowing the folding into a partially double-stranded rod-like structure [46]. During HDV replication in the infected cells, two other main forms of viral RNAs can be found: the antigenome, which is a repli-cation intermediate and the exact complement of the genome sequence [47,48], and the HDV mRNA coding for the two isoforms of the HDAg [49]. Ribozymes (small, self-cleaving RNA sequences) have been described in both the HDV genome and antigenome and are responsible for the cleavage of the multimeric linear RNA mole- cules that arise during replication [50]. N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 5 Fig. 1. Structure of HBV and HDV virions. Both viruses use HBV surface proteins (S-, M- and L-HBsAg) for their assembly. HBV icosahedral capsid is formed by multimerisation of its core protein (HBcAg) and contains one copy of the viral partially double-stranded DNA genome (or relaxed circular DNA, rcDNA) and the viral polymerase. HDV virions contain one copy of the viral circular, single-stranded RNA genome (that has 70% of sequence complementarity, allowing its folding into a rod-like structure), associated with both forms of its only protein (large and small delta antigen or S- and L-HDAg), forming the viral ribonucleoprotein (RNP). Viral life cycle The following paragraphs describe the main steps of the HDV been hypothesised for HBV, namely in lymphocytes [51,52], no such evidence exists for HDV [53]. However, HDV replication can take place in a wide range of mammalian cells, if the genome is life cycle and Fig. 2. depicts a simplified, schematic version. experimentally delivered, suggesting that its hepatotropism Viral entry HDV is considered to target primarily hepatocytes. Although the possibility of extra-hepatic replication in a natural infection has depends exclusively on the presence of the receptor [54]. HDV is considered to enter hepatocytes through the same mechanisms as HBV, given that both viruses share a similar envelope [2]. Infectivity of both viruses depends on the presence of L-HBsAg, in particular on the 75 amino acids located at its Fig. 2. HDV life cycle. HDV entry (step 1) is mediated by a first attachment step, resulting from viral interaction with HSPGs, and later specific interaction of L-HBsAg with the viral receptor, NTCP. This step is inhibited by Myrcludex B. The viral RNP is then transported to the nucleus (step 2) where it releases the viral genome that serves as template to transcription of HDV mRNA (step 3), from which HDAg is translated (step 4). Replication of viral RNA (step 5) is mediated by cellular DNA-dependent RNA polymerases in the presence of S-HDAg, through a rolling-circle mechanism, with formation of multimeric and antigenomic RNA intermediates. During replication, antigenomic RNA can be edited by ADAR1 (step 6), leading to the expression of L-HDAg molecules (as detailed in Fig. 3). Farnesylation of L-HDAg (step 7), a step inhibited by lonafarnib, is necessary for regulation of replication and viral assembly. The newly formed HDV RNPs are assembled in the nucleus (step 8), exported and then enveloped by HBV surface glycoproteins (step 9) through the interaction of farnesylated L-HDAg with HBsAg. HDV virions are thought to be secreted through the Golgi (step 10) in parallel with HBV SVPs. Although the precise mechanism of action of REP 2139 is not fully characterized, it has been shown not to interfere with viral entry of HBV or HDV but appears to affect HDV secretion by inhibiting secretion of HBsAg and also potentially by interacting with HDAg. The exact mechanism of action of interferons (both alpha and lambda) is not represented, as it is still not fully known (although it is believed to involve an inhibition of viral RNA replication). ADAR1, adenosine deaminase acting on RNA 1; AG, antigenome; ER, endoplasmic reticulum; G, genome; HBV, hepatitis B virus; HDV, hepatitis B virus; HSPGs, heparan sulfate proteoglycans; NTCP, sodium taurocholate co-receptor peptide; RNP, ribonucleoprotein; SVPs, subviral particles. 6 N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 N-terminal (in the PreS1 domain), where an essential myristoyla-tion site is located [40], as well as specific amino acid residues of S-HBsAg. However, M-HBsAg does not seem necessary [55,56]. A first, non-specific step consists in the viral attachment to the heparin sulfate proteoglycans (HSPGs) exposed on the outer face of the host cell membrane [57–59]. One particular HSPG, glypican-5, has been identified as an entry factor that only partially justifies HDV and HBV dependence on HSPGs, as its abrogation was not suf-ficient to completely prevent infection [60]. Attachment, although necessary, is not sufficient to allow viral entry and further interaction of the virus with its specific receptor is needed. For the first three decades following the identification of both HBV and HDV, this receptor was unknown. In 2012, the human sodium taurocholate cotransporting peptide (hNTCP, encoded by SLC10A1) was convincingly shown to be a functional receptor to both HBV and HDV in hepatocytes [61]. This molecule is located at the basolateral membrane of hepatocytes and is involved in the uptake of bile acids. The interaction of the bile acid binding domain of NTCP with the myristoylated N-terminal sequence of the PreS1 region of L-HBsAg was shown to be both necessary and sufficient for HBV and HDV infection [61,62]. The post-entry steps involved in the release of the HDV RNP in the cytoplasm and its transport into the nucleus, where transcription and replication subsequently occur, are not fully characterised. Replication HDV replication occurs in the nucleus and is completely inde-pendent of HBV. Since HDV does not possess its own RNA-dependent RNA polymerase or use the polymerase of its helper virus, the host cell DNA-dependent RNA polymerases likely medi-ate its replication. Several lines of evidence support the involve-ment of RNA polymerase II, but a debate is still ongoing concerning the role of the other cell RNA polymerases in HDV replication [54,63]. Both RNA polymerases I and III have been shown to bind HDV RNA. While RNA polymerase I seems impli-cated in the antigenomic transcription, no precise function has been reported so far for RNA polymerase III [64]. The mechanisms through which the virus is able to hijack the cell DNA-dependent RNA polymerase(s) for its RNA replication are still largely unknown and, although similar mechanisms have been shown to play a role in plant viroid replication [65], HDV con-stitutes a unique case in human virology. The secondary structure of HDV RNA might play a role in the capacity of the host RNA poly-merase II to use it as template, as the enzyme recognises sites located at the two poles of the rod-like structure of the genome [66]. Arguably, S-HDAg would also play an important role in this process [67]. Indeed, the regulation of viral replication involves both forms of HDAg: while L-HDAg, which is essential for viral assembly, has an inhibitory effect on replication [68,69], the tran-scription of the viral RNAs cannot occur in the absence of S-HDAg [70,71]. S-HDAg has been shown to interact with several subunits of both RNA polymerases I and II and the interaction with the latter may involve the recruitment of chromatin remodelling complexes onto HDV RNA [67,72]. To account for the need of S-HDAg, the transcription of the HDV mRNA is believed to precede the HDV RNA replication. The cellular RNA polymerase II mediates the tran-scription of this 800 nucleotide-long mRNA, which has the same characteristics as cellular mRNAs (a 50 cap and a poly-A tail) [54]. This step ensures the availability of S-HDAg, which then favours the initiation of replication. The replication of HDV RNA follows a rolling-circle mechanism starting with the synthesis of multimeric linear transcripts com-plementary to the genome. HDV RNA antigenomic ribozyme self-cleavage separates the different monomers from the multimeric transcripts. Monomers are then ligated into circular antigenomic molecules, serving as the template for genomic-strand progeny molecules [66]. The mechanism underlying the circularisation of the HDV genome, either by ribozyme mediated self-ligation or a cellular ligase, is still under debate [73]. RNA editing and L-HDAg synthesis A single open reading frame in the HDV antigenome directs the synthesis of both isoforms of HDAg (S-HDAg and L-HDAg). These two isoforms differ by an additional C-terminal stretch of 19 amino acids in L-HDAg. As described before, the replication of HDV RNA requires S-HDAg, whereas L-HDAg is essential for virion assembly. The C-terminal domain of L-HDAg enables the interaction with HBsAg [74]. The relative ratio between these two HDAg isoforms regulates the equilibrium between replication and virion assembly. The editing of the antigenomic RNA by adenosine deaminase acting on RNA 1 (ADAR1) drives the transition from S-HDAg mRNA to L-HDAg mRNA transcription [75]. This cellular enzyme has two iso-forms: the small, which is expressed constitutively and the large, whose expression is stimulated by type I IFN. Contradictory results still exist regarding the role of each ADAR-1 isoform in the HDV life cycle [76,77]. ADAR1 acts on a particular site of the HDV antige-nome, called the amber/W site. This site is a UAG amber stop codon, leading to translation termination and consequent S-HDAg production. ADAR1 deaminates an adenosine (UAG ? UIG) and the resulting inosine is recognised as a guanosine in the next replication cycle, leading to a ACC triplet on the genome (instead of the original AUC). Transcription of this triplet generates a tryptophan-encoding UGG codon in the mRNA that no longer works as a stop codon. Consequently, translation proceeds for an additional 19 amino acids, resulting in L-HDAg synthesis [75], as depicted in Fig. 3. Post-translational modifications of HDAg proteins Both HDAg proteins undergo post-translational modifications critical for their respective functions. Phosphorylation of two ser-ine residues of S-HDAg allows interactions with the cellular RNA polymerase II, enabling the replication of HDV RNA [78,79]. A far-nesylation signal (C211XXQ box) in the additional 19 amino acids of L-HDAg enables a farnesyl lipid group to be added covalently to the cysteine at position 211 by a cellular farnesyltransferase. This far-nesylated form of L-HDAg inhibits the replication of HDV RNA and is essential for virion assembly [74]. Indeed, agents that inhibit the addition of the farnesyl lipid group to the C-terminus of L-HDAg prevent its interaction with HBsAg, consequently inhibiting HDV virion secretion both in vitro and in vivo [80,81] and constitute a novel therapeutic approach for HDV infection (see Drugs in Clinical Development below). Assembly and release As mentioned previously, although HDV can replicate and syn-thesise new RNPs independently of HBV, its release from hepato-cytes depends on the presence of HBsAg in the same cell. HDV assembly depends on the specific interaction between the farnesy-lated N-terminus of L-HDAg and the S region of HBsAg [82], and it has been shown that, unlike HBV, HDV RNP can efficiently be assembled with the small form of HBsAg (S-HBsAg) [83]. However, the large form of HBsAg (L-HBsAg) is needed to form infectious virions (as mentioned earlier, it mediates the interaction between the virus and its hepatocyte receptor, NTCP). The relevance of the non-infectious, S-HBsAg enveloped, HDV particles in a natural infection is still to be demonstrated. In the context of a HBV infection, the three forms of HBsAg, which are produced in much higher amounts than required for HBV virion production, can self-assemble and be secreted as ‘‘empty” subviral particles (SVPs). These non-infectious SVPs (con-stituted of an envelope devoid of HBV capsid or nucleic acids) are secreted in large excess relative to the infectious virions and are N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 7 Fig. 3. Differential expression of S- and L-HDAg as a consequence of antigenome RNA editing by ADAR-1. The HDV antigenomic RNA has one single open reading frame from which the two isoforms of HDAg are expressed. Adenosine deaminase acting on RNA-1 (ADAR1) catalyses editing of the amber/W site on the antigenomic HDV RNA and adenosine 1012 is converted to inosine. After replication and mRNA transcription, the original stop codon (AUG, terminating the synthesis of S-HDAg) is converted into UGG, coding for a tryptophan (Trp) residue and allowing translation to proceed until the next stop codon, which results in the addition of 19 amino acids (L-HDAg). thought to play a role in HBV escape to the immune response. HBV SVPs are secreted through the Golgi, while infectious virions follow the multivesicular body pathway [84]. Given that the composition of the HDV envelope is close to that of SVPs and that titers of cir-culating HDV virions are higher than those of HBV virions, approaching those of HBV SVPs [2,85], it is likely that HDV uses the SVP secretion pathway for its assembly and release. Molecular interactions with HBV Studies conducted in experimental models have shown a decrease in HBV replication in the context of HDV infection, with minimal impact on the expression of HBsAg, as demonstrated by an increased HBsAg/HBV DNA ratio in the HBV-HDV co-infected cells, in comparison with HBV monoinfected cells [86–88]. This observation has been confirmed in patients, although the viral dominance patterns seem to fluctuate over time [89,90]. Several mechanisms may be used by HDV to inhibit its helper virus replication, while ensuring a constant pool of HBsAg for its own assembly. Firstly, the possibility of an epigenetic regulation of cccDNA transcriptional activity by HDAg has been suggested from both in vitro results and patients samples [91], raising the possibility of a differential transcription of PreS/S mRNA vs prege-nomic mRNA. Secondly, both isoforms of HDAg have been shown to interact with and strongly repress both HBV enhancer sequences, with a direct impact on HBV replication [92]. Thirdly, HDAg, being an RNA-binding protein that has recently been shown to interact with specific cellular RNAs [93–95], may bind to HBV mRNAs and selectively affect their stability. Finally, accumulating evidence suggests that, in HBV-infected patients, integrated HBV DNA is an abundant source of HBsAg, even in the absence of HBV replication [96–98]. Furthermore, HBsAg derived from integrated HBV DNA has been shown to support assembly and release of infectious HDV particles [99]. While the impact of this mechanism in vivo is still to be demonstrated, it is tempting to hypothesise that HDV can complete its cycle using HBsAg produced from integrated HBV DNA, devoid of HBV replication in the same hepatocyte. Indirect mechanisms of interference through a deregulation of the hepatocyte innate immune response are also possible. HBV has classically been considered not to be recognised by the innate immune system [100]. While this notion has been challenged by evidence suggesting that the virus may in fact actively counteract the interferon response [101,102], two recent studies support the concept of HBV as a ‘‘stealth virus” [103,104]. HDV, on the other hand, has been shown to induce a strong type I IFN response [86,105] as a result of the recognition of viral RNAs by melanoma differentiation antigen 5 (MDA5) [106]. The consequent increased expression of antiviral IFN-stimulated genes (ISGs), such as MxA, may contribute to the inhibition of HBV replication [92]. The interplay between HDV and the host cell IFN response is however far from being clarified. HDV replication is itself inhibited by the administration of exogenous IFN-alpha [86,107]. The mech-anisms could involve, among others, the increased synthesis of L-HDAg as a consequence of the stimulation of ADAR1 expression [108]. Furthermore, IFN-alpha has been shown to inhibit HDV propagation during cell division, suggesting yet another antiviral mechanism [109] [Zeng Z et al, 2018 International HBV Meeting]. It is tempting to hypothesise that the virus may have developed mechanisms to resist the strong IFN response induced by its own replication, and HDV has indeed been shown to interfere with the JAK/STAT signalling pathway, a mechanism that might play a role in viral persistence [110]. Clinical presentation and natural history of the disease Two modalities of HDV infection exist: simultaneous coinfec-tion with HBV and HDV superinfection of a person chronically car-rying HBV. Coinfection translates into acute hepatitis, during which aminotransferase levels can follow a typical biphasic course, corresponding to an initial HBV spread followed by HDV propaga-tion. As for HBV monoinfection, in most immunocompetent adult patients (90–95%), it progresses to resolution of both HBV and HDV infections. The risk of acute liver failure is however much higher than that during acute HBV monoinfection [111,112]. Acute 8 N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 HDV superinfection of a patient chronically infected with HBV is associated with an episode of acute hepatitis that can be mistaken for a HBV flare. In this setting, the risk of acute liver failure is par-ticularly high [111]. More than 90% of HBV carriers superinfected with HDV progress to chronic dual infection [111,112]. CHD is considered the most severe form of chronic viral hepati-tis, with a faster progression towards cirrhosis and a higher risk of decompensation and mortality [113]. Indeed, 10–15% of chroni-cally infected patients might develop cirrhosis within 5 years from infection and up to 80% after 30 years [114]. The association between HDV and HCC is still debated. On the one hand, decompensation of chronic liver disease, and not HCC, has been shown to be the most common complication of CHD [115,116]. On the other hand, despite the long-standing belief that HDV-infected patients do not present an increased risk of HCC, sev-eral cohort studies have recently found that this risk may indeed be as much as nine times higher than in HBV monoinfected patients [20,113,117,118]. Furthermore, persisting HDV replication was shown to be a risk factor for liver disease progression and HCC [119]. Other factors of disease progression are male sex, cirrhosis at presentation and lack of antiviral therapy [116]. Diagnosis of HDV infection Recommendations of the major societies currently differ in the screening strategy for HDV diagnosis. European guidelines advise for HDV screening of all HBV-infected patients [120]. In the United States, and despite increasing evidence pointing to a suboptimal diagnosis of HDV infection [20,21], screening is only advised in patients with specific risk factors (including migrants from regions with high HDV endemicity, a history of IVDU or high-risk sexual behaviour, individuals infected with HCV or HIV and patients with elevated aminotransferases with low or undetectable HBV DNA) [19]. Given the recent evidence suggesting that the global burden of disease may be higher than previously estimated, screening of all HBsAg-positive patients may be considered. Such a strategy would not only allow a more accurate determination of the preva-lence of HDV infection, but it would also lead to wider and earlier therapeutic interventions, decreasing the burden of disease com-plications. Furthermore, access to care would be significantly strengthened by the implementation of point of care diagnosis. Several markers can be used for the diagnosis of HDV infection. for other viruses, lack of standardisation is still problematic for HDV and PCR results are often not comparable between laborato-ries [124]. Recent steps have been taken towards standardisation, with the availability of a World Health Organization standard, allowing result reporting in international units (IU) and new pangenotypic commercial assays [125]. In cases where a liver biopsy sample is obtained, intrahepatic HDAg may be detected by immunohistochemistry and HDV RNA by in situ hybridisation. Although determination of HDV genotype is possible by PCR, its use is limited to research settings. Management of HDV-infected patients The management of acute hepatitis D relies on general support measures or referral for liver transplantation if acute liver failure develops. No antiviral treatment has proven useful [126]. There are currently no specific direct-acting antiviral treatments for HDV and, although several host-targeting molecules are under development, current recommendations for CHD treatment are limited to a prolonged course of pegylated IFN-alpha. Patient follow-up and treatment outcomes The ideal endpoint for CHD treatment would be the clearance of both HBV and HDV infections from the liver, translating into anti-HBs seroconversion, to prevent liver disease progression. Although on-treatment and post-treatment kinetics of serum HDV RNA have been used to monitor treatment response, cumulative evidence exists that, unlike HCV infection, they fail to predict long-term viro-logical outcome. Indeed, although undetectable HDV viremia is expected to be a marker of on-treatment response, a classical defi-nition of sustained virological response (persistently undetectable viral RNA for 24 weeks after treatment) should be used with cau-tion in CHD, as later relapses have been shown to occur in more than 50% of the patients treated with pegylated IFN-alpha [127]. Currently available antiviral treatments Pegylated IFN-alpha Although, as described above, its precise mechanism of action still needs to be clarified, IFN-alpha remains the only recom- mended treatment for CHD [19,120]. Pegylated IFN-alpha, having Anti-HDV antibodies can be detected by enzyme-linked a prolonged plasma half-life, allows a once-a-week administration, immunosorbent assay (ELISA) or radioimmunoassay (RIA). Anti-HDV total antibody is currently used as a first screening approach for the detection of HDV infection. However, two main limitations should be borne in mind, justifying the need for complementary approaches for diagnosis confirmation. Firstly, total anti-HDV anti-body can be undetectable in the early weeks of acute infection. Sec-ondly, anti-HDV IgG may persist after HDV infection, not allowing the distinction between active and resolved infection. A quantita-tive microarray antibody capture (QMAC) assay for the quantifica-tion of anti-HDV IgG has been recently validated for HDV diagnosis in Mongolia and the United States and was shown to cor-relate with detection of HDV RNA [8,121]. Anti-HDV IgM appears earlier during the acute infection and has been shown to correlate with disease activity during chronic infection [122]; however, it is frequently undetectable in this setting and hence does not allow diagnosis confirmation nor distinction between acute and chronic infection. Serum HDAg is only transiently detected in the acute phase of HDV infection and its measurement is of limited utility. Infection confirmation relies on the detection of HDV RNA by quantitative RT-PCR, which, together with a positive anti-HDV antibody, allows to distinguish between chronic and past infec- tions and to follow response to treatment [123]. However, unlike with better efficiency and compliance than standard IFN-alpha [123,128]. Indeed, in a meta-analysis performed in 2011, standard IFN-alpha treatment was associated with a 17% sustained suppres-sion of HDV RNA at six months follow-up (compared to 25% in pegylated IFN-alpha) and with more frequent and severe adverse events (e.g. anorexia, nausea, weight loss, alopecia, leukopenia and thrombocytopenia) [129]. Results are comparable for pegy-lated IFN-alpha 2a and 2b [130]. Data from clinical trials do not allow an accurate prediction of response and no robust stopping rules exist. However, HDV RNA negativity at 24 weeks of treatment has been identified as a predic-tor of sustained HDV RNA suppression during follow-up [131]. Nevertheless, optimal treatment duration has not been estab-lished. In most studies, pegylated IFN-alpha was used for 48 weeks and this is now the recommended treatment duration. As shown in Table 1, results diverge among studies and considering the vari-ability of PCR performances recently demonstrated [124,132], the reported sustained responses at 24 weeks of post-treatment follow-up may have been overestimated in earlier studies. In one large randomised clinical trial, a 48-week course of pegylated IFN-alpha led to a persistently undetectable HDV RNA 24 weeks after treatment in 25%–30% of patients [133]. Shorter treatment N. Mentha et al./Journal of Advanced Research 17 (2019) 3–15 9 Table 1 Summary of studies evaluating IFN-alpha treatment of chronic hepatitis D. Treatment IFN-alpha: 3–18 Mio units 3x/week Pegylated IFN-alpha 2b: 1.5 mg/kg qw Pegylated IFN-alpha 2a: 180 mg/kg qw Pegylated IFN-alpha 2b: 1.5 mg/kg qw or Pegylated IFN-alpha 2a: 180 mg/kg qw Abbreviations: qw, weekly; qd, daily. Treatment modalities 3–12 months 18 months 18 months + Ribavirin (1–1.2 g qd for 12 months) 12 months 12 months 12 months 12 months 12 months + adefovir (10 mg qd for 12 months) 12 months Number of patients 201 16 22 14 12 48 29 31 104 Sustained suppression of HDV RNA at 24-weeks of follow-up 17% 25% 18% 43% 17% 25% 26% 31% 23% References [129] [137] [137]

Tài liệu liên quan